Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.
Key features of the study:
This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics
The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market
Detailed Segmentation:
Global Hereditary Angioedema Market, By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
Global Hereditary Angioedema Market, By Route of Administration:
Subcutaneous
Intravenous
Oral
Global Hereditary Angioedema Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Global Hereditary Angioedema Market, By Geography:
North America
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
U.S.
Canada
Latin America
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Bradykinin Receptor
Attenuated Androgens
Others
By Route of Administration:
Subcutaneous
Intravenous
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
e-Commerce
By Country:
South Africa
Central Africa
North Africa
Company Profiles
CSL Behring*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Shire Plc.
Pharming Healthcare, Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Class
? Market Snippet, By Route of Administration
? Market Snippet, By Distribution Channel
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
o Key Highlights
o Pipeline Analysis
o Regulatory Guidelines
o Epidemiology
4. Global Hereditary Angioedema Market, By Drug Class, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o C1 Esterase Inhibitor
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Kallikrein Inhibitor
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Bradykinin Receptor
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Attenuated Androgens
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
5. Global Hereditary Angioedema Market, By Route of Administration, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Subcutaneous
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Intravenous
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Oral
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
6. Global Hereditary Angioedema Market, By Distribution Channel, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Hospital Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Retail Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o e-Commerce
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
7. Global Hereditary Angioedema Market, By Region, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? U.S.
? Canada
o Latin America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Brazil
? Mexico
? Argentina
? Rest of Latin America
o Europe
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Germany
? U.K.
? France
? Italy
? Spain
? Russia
? Rest of Europe
o Asia Pacific
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? China
? India
? Japan
? Australia
? South Korea
? ASEAN
? Rest of APAC
o Middle East
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? GCC
? Israel
? Rest of Middle East
o Africa
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? South Africa
? Central Africa
? North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? CSL Behring*
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Shire Plc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Pharming Healthcare, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? BioCryst Pharmaceuticals, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Ionis Pharmaceuticals, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Attune Pharmaceuticals, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Arrowhead Pharmaceuticals
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Adverum Biotechnologies
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market - Global forecast to 2025".
Request Discount 
Inquire Before Buy
